Grand Pharmaceutical Group (HKG:0512) will obtain the exclusive development and commercialization rights for two dry eye drugs from Corxel Pharmaceuticals Hong Kong for the Greater China region, a Wednesday bourse filing said.
The exclusive rights for the varenicline tartrate and simpinicline nasal sprays will cover the region comprising Mainland China, Hong Kong, Macau, and Taiwan.
Corxel is a biopharmaceutical company headquartered in the United States and China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.